SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt puts its marketing division ‘Merind’ on sale

07 Sep 2009 Evaluate

Wockhardt is learnt to have put its marketing division of pharmaceutical

formulations, Merind, up for sale. MNCs have shown interest in picking up the division, for which Wockhardt is learnt to have put a price tag of nearly Rs 800 crore, according to sources. Top line and EBIDTA of Merind could be Rs 300-350 crore and Rs 60-70 crore, respectively, according to sources. Wockhardt does not reveal the size of Merind’s business in its balance sheet since it is a business division.

The proposed sale is part of the troubled pharma company’s attempt to raise funds to repay debts totalling Rs 3,400 crore. Wockhardt recently sold its German subsidiary, Esparma, for Rs 120 crore, animal healthcare business for Rs 170 crore and its nutritional division for $130 million ( approximately Rs 635 crore) to raise funds. The company’s promoters, the Khorakiwala family, also sold 10 Wockhardt hospitals to Fortis for Rs 909 crore.

Merind’s is learnt to be the second largest marketing division within Wockhardt, selling more than 26 brands including top brands like Decdan, Tryptomer and Libotryb. These three brands had annual sales of Rs 21.5 crore, Rs 19.5 crore and Rs 13 crore respectively. It employs over 300 people. crackcrack

Wockhardt Share Price

1344.05 -26.90 (-1.96%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×